Stifel: 'ALKS Shares Should Get a Boost on CNTA Disclosure'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop
November 5, 2025 8:03 AM ESTTruist Securities analyst Danielle Brill reiterated a Buy rating and $30.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).
The analyst comments "CNTA shared the highly anticipated preliminary Ph 2a data with ORX750 in narcolepsy type 1 & 2 (NT1/NT2) and idiopathic hypersomnia (IH) this morning.... More
